Diligence memo · auto-generated · as of July 2, 2026
Dignify Therapeutics, LLC
Dignify Therapeutics, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Dignify Therapeutics, LLC operates in Pharmaceuticals, based in RESEARCH TRIANGLE PARK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Dignify Therapeutics, LLC has raised $3.4M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.4M on 2014-10-10.
Most recent recorded round closed around 2014-10-10.
Valuation (modeled)modeled
Provath models Dignify Therapeutics, LLC at approximately $131M (range $2.6M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.98× the median modeled value of Seed Pharmaceuticals companies in 2013–2015 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 11.7 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 36% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 60% of those peers.
Closest niche peers: Assured Pharma, Inc., Wellesley Pharmaceuticals Llc, Generico, Llc, Aggamin Pharmaceuticals, LLC, Abeona Therapeutics LLC.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.